Inclusion of those with those with Duffy-null Associated Neutrophil Count (DANC) in Clinical Trials
About this episode
The episode discusses the implications of the Duffy null phenotype on absolute neutrophil count and clinical trial inclusivity.
Join us for an important conversation with Dr. Andrew Hintel and Dr. Lauren Merz as we explore how the Duffy null phenotype shapes absolute neutrophil count (ANC) and what this means for clinical care and trial design. Although common among individuals of African, Middle Eastern, and North African ancestry, the Duffy null phenotype is often misunderstood, leading to unnecessary procedures, inappropriate dose modifications, and exclusion from potentially life-saving therapies. Through real-world examples, we discuss how standard ANC cutoffs can disadvantage Duffy null patients, the implications for chemotherapy, immunosuppressive drugs, and clozapine, and how recent updates to Common Terminology Criteria for Adverse Events grading criteria intersect with this biology. The episode also highlights ongoing efforts, supported by ASH and the Doris Duke Foundation, to establish adult and pediatric reference intervals and promote more inclusive clinical trial practices. This discussion will equip hematologists and oncologists with practical insights to better interpret neutrophil counts, advocate for equitable trial access, and optimize treatment decisions for patients with the Duffy…
People in this episode
Guests: Dr. Andrew Hintel, Dr. Lauren Merz
Topics covered
- Duffy null phenotype
- absolute neutrophil count
- clinical trials
- patient care
- chemotherapy
- immunosuppressive drugs
Keywords
- Duffy-null
- neutrophil count
- clinical trials
- ANC cutoffs
- patient advocacy
- treatment decisions
Mentioned in this episode
Organizations: American Society of Hematology, Doris Duke Foundation
More episodes of HemeTalks: Conversations in Hematology Education
- Approaching MDS: Advances in Diagnostics, Therapeutics and Monitoring
- New Horizons in Smoldering Multiple Myeloma
- Interpreting Abnormal SPEP – Is It Just MGUS?
- Sticky Situations: The Role of Thrombophilia Testing in VTE Management
- Lost in Translation: The aHUS Experience
- Thalassemia in Pediatric Hematology
Explore listener stats, chart rankings, contacts and more on the HemeTalks: Conversations in Hematology Education podcast page.